OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety and efficacy of OraVescent
fentanyl to treat breakthrough pain episodes in cancer patients who are already opioid
tolerant.